<DOC>
	<DOCNO>NCT00006006</DOCNO>
	<brief_summary>Phase II trial study effectiveness thalidomide plus interferon alfa treat patient progressive liver cancer surgically remove . Thalidomide may stop growth liver cancer stop blood flow tumor . Interferon alfa may interfere growth cancer cell . Combining thalidomide interferon alfa may kill tumor cell .</brief_summary>
	<brief_title>Thalidomide Plus Interferon Alfa Treating Patients With Progressive Liver Cancer That Can Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility activity thalidomide patient unresectable hepatocellular carcinoma . II . Evaluate toxicity thalidomide patient . III . Assess use interferon alfa patient develop disease progression treat thalidomide . OUTLINE : This multicenter study . Patients receive oral thalidomide daily . Patients stable dose thalidomide least 4 week evidence progressive disease receive interferon alfa subcutaneously twice daily . Treatment continue absence disease progression initiation interferon alfa therapy unacceptable toxicity .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hepatocellular carcinoma OR Diagnosis hepatocellular carcinoma base characteristic mass alphafetoprotein great 500 set know cirrhosis chronic hepatitis B C Measurable disease At least 20 mm one dimension Not amenable curative surgical resection PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count great 1,200/mm^3 Hemoglobin least 8.0 mg/dL Platelet count least 25,000/mm^3 Hepatic : Bilirubin great 5 mg/dL Liver function test great 5 time normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Regardless fertility status : All woman ( unless undergone hysterectomy amenorrheic postmenopausal least 2 year ) must use least 1 highly active method contraception AND 1 additional effective method contraception least 4 week , , least 4 week study All men ( even undergone successful vasectomy ) must use effective barrier contraception least 4 week study No medical condition would preclude study No prior malignancy past 5 year except curatively resect basal cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biologic therapy regimen No prior interferon thalidomide hepatocellular cancer Chemotherapy : No 1 prior chemotherapy regimen Other : No concurrent barbiturates alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>